An external panel that advises the United States Food and Drug Administration narrowly voted to endorse a new Pfizer vaccine for respiratory syncytial virus (RSV) for older adults. The move is the first step toward the FDA approving a vaccine that prevents severe RSV in the lower respiratory systems of adults aged 65 and older. […]